AGPS

Across TCGA pan-cancer cohorts, AGPS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AGPS data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AGPS mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AGPS expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LUAD, PDAC, and GBM are the cancer types where AGPS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.626	0.871	.002	34	view →
PDAC	DFS	Tertile	IV	0.250	0.934	.024	12	view →
GBM	OS	Median	All	0.417	0.642	.008	11	view →
LSCC	OS	Tertile	III,IV	0.983	0.635	.025	2	view →
HNSC	DFS	Quartile	II,III,IV	0.706	0.480	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AGPS–LUAD (OS)

Open the LUAD breakdown →